What is PT Kalbe Farma Tbk. (PTKFF)?

PT Kalbe Farma Tbk. (PTKFF) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of PTKFF?

The current price of PTKFF is $0.04. Prices are updated in real time on Stocks360.

What is PTKFF's price-to-earnings (PE) ratio?

PTKFF's trailing twelve-month PE ratio is 9.17, based on current price and earnings per share data available on Stocks360.

What is PTKFF's market capitalization?

PTKFF's market capitalization is $1,809,954,743.00, placing it in the small-cap tier.

Does PTKFF pay a dividend?

Yes. PTKFF has a trailing twelve-month dividend yield of 0.03%. Dividend data is sourced from financial market providers and displayed on Stocks360.

PT Kalbe Farma Tbk. (PTKFF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - General

$0.04

Market Cap

$1.81B

PE (TTM)

9.17

EPS (TTM)

N/A

Dividend Yield

2.74%

Beta

-0.19

Day Range

$0.04 – $0.05

52-wk Range

$0.04 – $0.08

Avg Volume

N/A

Volume

10.00K

PT Kalbe Farma Tbk. (PTKFF) is a publicly traded company in the Healthcare sector. Latest price: $0.04. Market cap $1.81B. Trailing PE 9.17. Dividend yield 2.74%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.08 2026-10-30 · $0.04 (-50.12%)

Earnings

Most Recent

Jul 31, 2026

EPS $0.00 vs est. $0.00

Missed by $0.00

Next Earnings

Nov 3, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About PT Kalbe Farma Tbk.

Indonesia-based pharmaceutical powerhouse, PT Kalbe Farma Tbk., along with its affiliated companies, is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products throughout the country. The organization structures its operations across four primary business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers a diverse range of medications, including generic, branded, and licensed drugs such as Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG, which are supplied to hospitals, pharmacies, and drug retailers. Beyond prescription items, its product line includes over-the-counter medicines, energy drinks, ready-to-consume beverages, dietary supplements, and other preventive health products. Furthermore, the company provides specialized nutritional offerings catering to all age groups—from infants and toddlers to children, adolescents, adults, expectant and lactating mothers, and seniors—as well as individuals with particular medical dietary requirements. The firm also extends contract services to other pharmaceutical companies, cover…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	9.17×
P/S (TTM)	0.88×
P/B	1.36×
PEG	1.37×
P/FCF (TTM)	13.46×
EV / EBITDA	5.33×
EV / Sales	0.77×
Earnings Yield	10.93%
Free Cash Flow Yield	7.43%
Dividend Yield	2.74%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$29.03T
Revenue (TTM)	$37.72T
Net Income (TTM)	$3.61T
Free Cash Flow (TTM)	$2.46T
Net Debt	-$4.01T
Working Capital	$14.33T
Gross Margin	37.52%
Operating Margin	12.07%
Net Margin	9.57%
Return on Equity	15.21%
Return on Invested Capital	13.20%